News & Events

College Hill Supports e-Therapeutics’ Facility Opening in Oxford by the British Prime Minister

College Hill Supports e-Therapeutics’ Facility Opening in Oxford by the British Prime Minister

26 February 2012, London: The Life Sciences team of international business communications consultancy, College Hill was pleased to have supported its drug discovery and development client e-Therapeutics plc (ETX:LSE), in the organisation of the Company’s opening ceremony for its new Oxford facility. The new facility was officially opened by the British Prime Minister Rt Hon David Cameron MP on 24 February 2012. 

The Prime Minister opened the new facility in Long Hanborough, near Oxford, which is within his constituency, unveiling a commemorative plaque. He was given a tour of the site, which included a demonstration of the Company’s network pharmacology platform, and met e-Therapeutics’ staff and some of the Company’s investors.

College Hill has supported e-Therapeutics since 2011, being first appointed to announce the Company’s £21m financing and has been retained to provide corporate and financial communications counsel. The fundraising enabled the Company to renew its drug discovery effort and to advance the development of its lead candidates. The opening of the Oxford facility represents an expansion from the Company’s Newcastle roots, into a second site which is primarily focused on drug discovery using e-Therapeutics’ network pharmacology platform. This platform differs from ‘conventional’ drug discovery, which is based on targeting a single protein, as it uses sophisticated computational techniques to analyse whole protein networks. The aim of the platform is to discover drugs that impact the entire network of proteins important in a disease, providing a more biologically robust and effective treatment for complex diseases.

The opening comes in a critical year for e-Therapeutics as it is also on track to progress its lead drugs into the clinic so is an exciting time for the Company. These lead candidates include ETS2101, a small-molecule anticancer drug with potential against various tumour types, including brain cancers; ETS6103, a small molecule being developed to treat depression; and ETX1153a a small molecule to treat topical MRSA.

The e-Therapeutics team is led by College Hill Life Sciences’ head of financial communications, Melanie Toyne Sewell, supported by Jayne Crook, who took a lead role in supporting the event.

Commenting on the opening, Melanie Toyne Sewell said: “We were delighted to be able to support e-Therapeutics in the organisation of this special event. It underlines our ability to provide our clients with a flexible and fully integrated approach to business communications, right through from offering strategic counsel and media outreach to design elements, including the production of the day’s hand-out programme, as well as organising the detailed logistics required for such an important day for the Company with not only the British Prime Minister but its key investors in attendance.” She also noted the vital role of sourcing the plaque to commemorate the opening and in ensuring the curtain opened smoothly on the day!

Daniel Elger, CFO of e-Therapeutics added: “We benefitted from the wide breadth of expertise at College Hill when planning this important event. Their hard work and careful attention to detail was instrumental in making the day a success.”

Further information:
Melanie Toyne-Sewell, Associate Partner / Head of Financial Communications
College Hill Life Sciences
Tel: 020 7457 2020
Email: melanie.toynesewell[at]

back to news